Jonathan M Hand, MD

Offices

1 location · Ochsner Clinic LLC · 2,845 clinicians in this group

Looking this up.

Hospitals listed: Ochsner Medical Center. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Hand’s office at (504) 842-3000 to ask if they take your plan before you enroll.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Ochsner Medical Center AcuteNew Orleans, LAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Ochsner Health System, which runs 36 hospitals in 3 statesPatients rate it 3 of 5 · 72% would definitely recommend it
Overall rating: 4 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.34 (0.89 to 1.8) · 9,200 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Abdominal Hysterectomy: 3.744, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.212, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.298, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.176, Oct 2024 – Sep 2025Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 9.9 (7.9 to 12.4) · 3,298 cases, Jan 2022 – Dec 2024

See every measure and the patient survey for Ochsner Medical Center Acute

Behind the star rating — Deaths: 2 better, 5 the same, 1 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 6 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Ochsner Medical Center Acute

Pressure ulcer rateComplications and deaths	1.34 (0.89 to 1.8) · 9,200 cases	Worse	Jul 2022 – Jun 2024
SSI - Abdominal HysterectomyInfections	3.744	Worse	Oct 2024 – Sep 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.212	Better	Oct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.298	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.176	Better	Oct 2024 – Sep 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	9.9 (7.9 to 12.4) · 3,298 cases	Better	Jan 2022 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	0.86 (0.07 to 1.65) · 2,712 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	1.15 (0.93 to 1.37)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	173.07 (136.7 to 209.45) · 172 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	2.5 · 50 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	10.1 · 123 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	12.1 · 159 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	10.6 · 596 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	12.2 · 419 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	11.3 · 878 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	3.4 · 8,405 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.21 (0.03 to 0.39) · 10,838 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.18 (0 to 0.36) · 11,193 cases	No different	Jul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	2.65 (1.04 to 4.27) · 3,022 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	1.27 (0.1 to 2.45) · 1,392 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	3.06 (1.92 to 4.21) · 2,824 cases	No different	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	9.85 (5.53 to 14.16) · 1,336 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	4.94 (2.4 to 7.48) · 1,367 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	2.87 (1.55 to 4.2) · 893 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.4 · 72 cases	None	Apr 2023 – Mar 2025
MRSA BacteremiaInfections	0.742	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	1.112	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	14.2 · 606 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	21.7 · 2,168 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	24.2 · 192 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	24.2 · 724 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	31.3 · 443 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	17.5 · 1,209 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	6.4 (5.1 to 8.1) · 663 cases	No different	Jan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	9.6 (7.9 to 11.7) · 663 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 64 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	13.3 · 116 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	20.4 · 603 cases	None	Jul 2023 – Jun 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.8 (0.7 to 1) · 1,666 cases	No different	Jan 2024 – Dec 2024

What patients said (1,973 patients answered, 18% of those asked)

Sort by

Patient survey stars by topic at Ochsner Medical Center Acute

Cleanliness	3
Nurse communication	3
Doctor communication	3
Communication about medicines	2
Discharge information	4
Overall hospital rating	3
Quietness	4
Recommend hospital	4

Sort by

Share of patients giving the best answer at Ochsner Medical Center Acute

Room was "always" clean	69%
Nurses "always" communicated well	78%
Doctors "always" communicated well	80%
Staff "always" explained	60%
Yes, staff "did" give patients this information	88%
Yes, staff "did" give patients information about help after discharge	87%
Doctors "always" explained things so they could understand	75%
Doctors "always" listened carefully	79%
Doctors "always" treated them with courtesy and respect	85%
Patients who gave a rating of "9" or "10" (high)	72%
Staff "always" explained new medications	74%
Nurses "always" explained things so they could understand	74%
Nurses "always" listened carefully	77%
Nurses "always" treated them with courtesy and respect	83%
"Always" quiet at night	62%
"YES", patients would definitely recommend the hospital	72%
Staff "always" explained possible side effects	46%
Yes, staff "did" give patients information about possible symptoms	89%

Original Medicare doctor bills

$27,198

Medicare paid this office $27,198 for 153 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	56	$10,729	$89
Initial hospital care with moderate level of medical decision making at least 75 minutes	74	$9,703	$129
New patient visit (60+ min)	16	$2,043	$128
Long return visit (40+ min)	20	$1,867	$85

Who their Medicare patients are

153 Original Medicare patients in 2024. Average age 66 · Under 65 35% · Women 46% · Also on Medicaid 27% · Health risk score 3.65. Above the middle of the specialty; the typical infectious disease clinician is at 3.

Conditions among them: High blood pressure 75% · Chronic kidney disease 62% · Diabetes 53% · Heart failure 42% · Coronary heart disease 37% · Depression 35% · COPD 25% · Atrial fibrillation 24% · Cancer 19% · Stroke 15% · Dementia 12%.

The office billed $89,223, Medicare allowed $34,959 and paid $27,198; for 272 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	153	272	66	3.65	$89,223	$27,198
2023	151	302	65	3.70	$92,398	$31,740
2022	192	309	64	3.76	$99,264	$33,852
2021	200	437	62	3.96	$134,314	$46,695
2020	174	391	61	4.36	$115,361	$38,580
2019	259	474	62	4.44	$133,940	$47,828
2018	308	661	62	3.84	$167,764	$59,911
2017	305	680	61	4.01	$201,823	$61,506
2016	237	579	60	4.29	$176,167	$52,334
2015	75	207	61	3.90	$58,695	$16,956

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Sort by

Original Medicare services billed in 2023

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	72	$13,454	$93
Initial hospital care with moderate level of medical decision making at least 75 minutes	78	$11,531	$134
Long return visit (40+ min)	29	$3,826	$109
Long return visit (40+ min)	12	$1,343	$112

2022: 5 services

Sort by

Original Medicare services billed in 2022

Initial hospital care with moderate level of medical decision making at least 75 minutes	100	$16,538	$153
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	87	$10,707	$80
Long return visit (40+ min)	20	$2,422	$110
Long return visit (40+ min)	11	$1,394	$116
Return visit (30+ min)	15	$1,100	$73

2021: 4 services

Sort by

Original Medicare services billed in 2021

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	97	$19,338	$82
Initial hospital care with moderate level of medical decision making at least 75 minutes	107	$18,848	$156
Long return visit (40+ min)	34	$4,647	$113
New patient visit (60+ min)	11	$1,589	$144

2020: 6 services

Sort by

Original Medicare services billed in 2020

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	82	$16,380	$84
Initial hospital care with moderate level of medical decision making at least 75 minutes	78	$14,322	$161
Return visit (30+ min)	30	$2,061	$62
Long return visit (40+ min)	19	$1,914	$87
New patient visit (60+ min)	15	$1,892	$126
Short return visit (20+ min)	13	$545	$42

2019: 5 services

Sort by

Original Medicare services billed in 2019

Initial hospital care with moderate level of medical decision making at least 75 minutes	118	$20,153	$161
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	108	$17,140	$82
Return visit (30+ min)	61	$4,271	$62
New patient visit (60+ min)	18	$2,376	$132
Long return visit (40+ min)	21	$2,073	$83

2018: 5 services

Sort by

Original Medicare services billed in 2018

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	153	$28,960	$82
Initial hospital care with moderate level of medical decision making at least 75 minutes	100	$16,825	$160
Return visit (30+ min)	82	$6,613	$60
Long return visit (40+ min)	30	$2,913	$81
New patient visit (45+ min)	27	$2,458	$91

2017: 6 services

Sort by

Original Medicare services billed in 2017

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	139	$29,648	$83
Initial hospital care with moderate level of medical decision making at least 75 minutes	82	$13,460	$158
Return visit (30+ min)	79	$6,565	$59
Long return visit (40+ min)	49	$5,150	$87
New patient visit (60+ min)	25	$3,320	$133
New patient visit (45+ min)	23	$2,126	$92

2016: 6 services

Sort by

Original Medicare services billed in 2016

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	101	$25,583	$81
Initial hospital care with moderate level of medical decision making at least 75 minutes	68	$11,706	$156
Return visit (30+ min)	68	$6,244	$61
New patient visit (45+ min)	45	$4,445	$99
New patient visit (60+ min)	22	$2,820	$128
Long return visit (40+ min)	11	$980	$89

2015: 3 services

Sort by

Original Medicare services billed in 2015

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	53	$11,433	$78
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,060	$158
Return visit (30+ min)	17	$2,055	$62

Medicaid work

$5,003 in 2024

Medicaid paid $5,003 for 98 billed services this clinician did in 2024, up to 16 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	85	$3,724
1ST HOSP IP/OBS HIGH 75	13	$1,280

Sort by

Medicaid work by year

2024	98	2	16	$5,003
2023	93	2	21	$6,229
2022	140	2	20	$9,007
2021	333	2	17	$11,090
2020	138	2	24	$6,204
2019	340	2	35	$14,629
2018	293	1	35	$11,981

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

1ST HOSP IP/OBS HIGH 75	66	$5,050
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	27	$1,180

2022

Sort by

Largest Medicaid services in 2022

1ST HOSP IP/OBS HIGH 75	100	$7,431
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	40	$1,576

2021

Sort by

Largest Medicaid services in 2021

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	228	$6,132
1ST HOSP IP/OBS HIGH 75	105	$4,958

2020

Sort by

Largest Medicaid services in 2020

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	125	$5,561
1ST HOSP IP/OBS HIGH 75	13	$643

2019

Sort by

Largest Medicaid services in 2019

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	327	$14,234
Return visit (30+ min)	13	$395

2018

Sort by

Largest Medicaid services in 2018

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	293	$11,981

Drugs they prescribed that Part D paid

$895,191

Pharmacies billed $895,191 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 650) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.

411 generic and 239 brand-name prescriptions · $895,191 in drug cost · 302 antibiotic prescriptions to 84 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Biktarvy	114	$449,784	$3,945
Triumeq	32	$117,114	$3,660
Tivicay	23	$75,895	$3,300
Juluca	15	$65,519	$4,368
Genvoya	12	$45,168	$3,764

See all 24 drugs

Sort by

Every Part D drug this clinician prescribed

Biktarvy	114	$449,784	$3,945
Triumeq	32	$117,114	$3,660
Tivicay	23	$75,895	$3,300
Juluca	15	$65,519	$4,368
Genvoya	12	$45,168	$3,764
Daptomycin	24	$43,092	$1,796
Descovy	11	$27,793	$2,527
Vemlidy	14	$17,849	$1,275
Etravirine	14	$9,687	$692
Ertapenem	35	$7,222	$206
Ceftriaxone	47	$4,912	$105
Meropenem	12	$2,220	$185
Cefepime	11	$2,037	$185
Lamivudine	14	$1,365	$97
Doxycycline Monohydrate	33	$1,234	$37
Cefadroxil	26	$616	$24
Doxycycline Hyclate	17	$589	$35
Sodium Chloride	12	$548	$46
Valacyclovir	11	$508	$46
Amoxicillin	11	$320	$29
Diazepam	13	$183	$14
Fenofibrate	13	$160	$12
Sulfamethoxazole-Trimethoprim	19	$115	$6
Ibuprofen	12	$75	$6

Year by year

Sort by

Part D prescribing by year

2024	650	111	0% (0)	37%	$895,191
2023	484	76	0% (0)	None	$745,128
2022	634	92	0% (0)	None	$760,028
2021	582	95	None	32%	$663,430
2020	618	115	None	26%	$524,141
2019	655	141	0% (0)	24%	$490,524
2018	682	145	None	26%	$406,188
2017	476	137	None	29%	$264,915
2016	444	114	0% (0)	None	$214,008
2015	196	39	None	37%	$34,559
2014	71	11	0% (0)	34%	$11,063
2013	223	25	0% (0)	None	$25,700

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 19 drugs

Sort by

Part D drugs prescribed in 2023

Biktarvy	88	$357,713	$4,065
Triumeq	30	$113,513	$3,784
Tivicay	13	$62,692	$4,822
Genvoya	12	$48,731	$4,061
Juluca	12	$42,501	$3,542
Ertapenem	37	$21,988	$594
Vemlidy	11	$17,283	$1,571
Etravirine	11	$14,164	$1,288
Daptomycin	15	$7,795	$520
Lamivudine	11	$1,895	$172
Ceftriaxone	20	$1,642	$82
Ampicillin-Sulbactam	16	$990	$62
Cefadroxil	20	$682	$34
Doxycycline Hyclate	17	$604	$36
Valacyclovir	14	$598	$43
Fenofibrate	12	$359	$30
Sulfamethoxazole-Trimethoprim	21	$172	$8
Diazepam	12	$122	$10
Ibuprofen	12	$64	$5

2022: 27 drugs

Sort by

Part D drugs prescribed in 2022

Biktarvy	100	$383,794	$3,838
Tivicay	26	$108,219	$4,162
Triumeq	17	$60,906	$3,583
Symtuza	11	$50,437	$4,585
Vemlidy	13	$18,030	$1,387
Etravirine	13	$14,656	$1,127
Ertapenem	23	$10,787	$469
Daptomycin	20	$9,842	$492
Meropenem	19	$9,226	$486
Xerava	11	$7,084	$644
Vancomycin	16	$4,187	$262
Cefepime	14	$3,832	$274
Amikacin Sulfate	13	$1,839	$141
Ampicillin-Sulbactam	11	$1,407	$128
Lamivudine	13	$1,169	$90
Doxycycline Monohydrate	19	$906	$48
Doxycycline Hyclate	19	$664	$35
Cefadroxil	14	$612	$44
Ceftriaxone	26	$574	$22
Azithromycin	11	$328	$30
Fenofibrate	13	$323	$25
Sodium Chloride	20	$249	$12
Sulfamethoxazole-Trimethoprim	22	$219	$10
Atorvastatin	18	$116	$6
Diazepam	13	$112	$9
Ibuprofen	11	$97	$9
Metoprolol	13	$58	$4

2021: 21 drugs

Sort by

Part D drugs prescribed in 2021

Biktarvy	79	$283,257	$3,586
Tivicay	20	$79,777	$3,989
Triumeq	17	$57,657	$3,392
Daptomycin	19	$49,728	$2,617
Ertapenem	24	$14,579	$607
Vemlidy	11	$14,429	$1,312
Cefepime	16	$3,707	$232
Doxycycline Hyclate	30	$1,409	$47
Ethambutol	12	$1,113	$93
Azithromycin	23	$1,106	$48
Doxycycline Monohydrate	19	$933	$49
Rifampin	11	$769	$70
Lamivudine	11	$638	$58
Ceftriaxone	11	$457	$42
Fenofibrate	13	$437	$34
Cefadroxil	13	$326	$25
Sulfamethoxazole-Trimethoprim	17	$210	$12
Diazepam	12	$134	$11
Sodium Chloride	16	$133	$8
Metoprolol	13	$56	$4
Atorvastatin	12	$49	$4

2020: 21 drugs

Sort by

Part D drugs prescribed in 2020

Tivicay	33	$116,712	$3,537
Biktarvy	22	$75,524	$3,433
Daptomycin	19	$56,378	$2,967
Symtuza	13	$53,211	$4,093
Triumeq	13	$41,388	$3,184
Genvoya	12	$40,803	$3,400
Intelence	16	$22,335	$1,396
Vemlidy	12	$14,024	$1,169
Ertapenem	24	$12,847	$535
Ampicillin-Sulbactam	23	$3,126	$136
Cefepime	14	$2,563	$183
Doxycycline Hyclate	28	$2,236	$80
Vancomycin	17	$2,209	$130
Doxycycline Monohydrate	27	$1,857	$69
Ceftriaxone	25	$1,441	$58
Cefadroxil	34	$1,402	$41
Fluconazole	30	$1,382	$46
Azithromycin	28	$830	$30
Lamivudine	12	$797	$66
Minocycline	14	$625	$45
Diazepam	11	$135	$12

2019: 24 drugs

Sort by

Part D drugs prescribed in 2019

Tivicay	39	$111,397	$2,856
Daptomycin	20	$71,806	$3,590
Atripla	13	$38,585	$2,968
Triumeq	11	$33,794	$3,072
Intelence	23	$30,950	$1,346
Prezista	12	$20,022	$1,668
Ertapenem	22	$15,535	$706
Vemlidy	13	$14,453	$1,112
Ampicillin	34	$8,488	$250
Cefepime	36	$7,855	$218
Vancomycin	29	$4,487	$155
Meropenem	11	$4,170	$379
Ceftriaxone	25	$3,430	$137
Doxycycline Hyclate	25	$2,260	$90
Cefazolin	22	$1,213	$55
Doxycycline Monohydrate	27	$1,104	$41
Cefadroxil	20	$1,034	$52
Azithromycin	25	$883	$35
Fluconazole	11	$857	$78
Valacyclovir	17	$849	$50
Ritonavir	11	$756	$69
Lamivudine	12	$682	$57
Isoniazid	21	$216	$10
Sulfamethoxazole-Trimethoprim	12	$90	$8

2018: 18 drugs

Sort by

Part D drugs prescribed in 2018

Tivicay	41	$104,278	$2,543
Atripla	16	$43,565	$2,723
Triumeq	14	$40,491	$2,892
Prezista	19	$30,138	$1,586
Piperacillin-Tazobactam	53	$15,787	$298
Intelence	12	$14,900	$1,242
Vancomycin	75	$12,246	$163
Invanz	17	$12,220	$719
Abacavir	21	$8,053	$383
Meropenem	30	$6,468	$216
Norvir	16	$5,233	$327
Cefepime	18	$3,406	$189
Cefadroxil	21	$2,076	$99
Ceftriaxone	27	$815	$30
Azithromycin	25	$481	$19
Lamivudine	14	$450	$32
Isoniazid	22	$325	$15
Ciprofloxacin	18	$215	$12

2017: 14 drugs

Sort by

Part D drugs prescribed in 2017

Atripla	25	$64,330	$2,573
Triumeq	11	$28,406	$2,582
Truvada	16	$25,352	$1,585
Invanz	22	$14,248	$648
Vancomycin	30	$7,484	$249
Cefepime	19	$6,369	$335
Piperacillin-Tazobactam	16	$5,109	$319
Meropenem	13	$1,708	$131
Ampicillin-Sulbactam	27	$1,286	$48
Azithromycin	34	$697	$21
Metronidazole	12	$362	$30
Isoniazid	24	$361	$15
Cefadroxil	15	$345	$23
Ciprofloxacin	19	$322	$17

2016: 12 drugs

Sort by

Part D drugs prescribed in 2016

Atripla	16	$38,315	$2,395
Tivicay	15	$31,327	$2,088
Truvada	11	$16,188	$1,472
Vancomycin	41	$7,638	$186
Cefepime	13	$2,438	$188
Piperacillin-Tazobactam	11	$2,272	$207
Cefazolin	33	$1,921	$58
Fluconazole	20	$1,863	$93
Zafirlukast	12	$1,085	$90
Azithromycin	21	$545	$26
Atorvastatin	11	$210	$19
Sulfamethoxazole-Trimethoprim	18	$198	$11

2015: 3 drugs

Sort by

Part D drugs prescribed in 2015

Advair Diskus	11	$4,445	$404
Vancomycin	18	$3,430	$191
Levothyroxine	14	$174	$12

2013: 4 drugs

Sort by

Part D drugs prescribed in 2013

Carvedilol	15	$158	$11
Simvastatin	22	$119	$5
Spironolactone	11	$66	$6
Lisinopril	14	$58	$4

Money from drug and device companies

$1,636 in 2025

Sort by

Industry payments by year

2025	4	7	$1,400	$1,636
2024	2	4	$4,500	$4,613
2023	1	3	$3,500	$3,524
2020	1	1	None	$87
2019	1	2	None	$20

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Pfizer	Prevnar 20	$1,400	2 payments Consulting for Prevnar 20 · 2025-09-19 · $350 Consulting for Prevnar 20 · 2025-09-19 · $1,050
AstraZeneca Pharmaceuticals LP	None	$120	2 payments Meals · 2025-10-20 · $53 Travel · 2025-10-20 · $67
La Jolla Pharmaceutical	Xacduro	$93	2 payments Meals for Xacduro · 2025-10-21 · $29 Meals for Xacduro · 2025-04-27 · $64
Amgen	Uplizna	$23	1 payment Meals for Uplizna · 2025-09-15 · $23

See all 7 published payments

Sort by

Every published payment

La Jolla Pharmaceutical	Meals · 2025-10-21	Xacduro	$29
AstraZeneca Pharmaceuticals LP	Meals · 2025-10-20	None	$53
AstraZeneca Pharmaceuticals LP	Travel · 2025-10-20	None	$67
Pfizer	Consulting · 2025-09-19	Prevnar 20	$350
Pfizer	Consulting · 2025-09-19	Prevnar 20	$1,050
Amgen	Meals · 2025-09-15	Uplizna	$23
La Jolla Pharmaceutical	Meals · 2025-04-27	Xacduro	$64

See earlier years (2024, 2023, 2020, 2019)

2024: $4,613

Sort by

Payments by company in 2024

La Jolla Pharmaceutical	Xacduro	$2,793	3 payments Honoraria for Xacduro · 2024-11-01 · $2,680 Meals for Xacduro · 2024-10-16 · $99 Meals for Xacduro · 2024-10-16 · $13
AstraZeneca UK	None	$1,820	1 payment Consulting · 2024-10-24 · $1,820

2023: $3,524

Sort by

Payments by company in 2023

Pfizer	Octagam Immune Globulin (Human)	$3,524	3 payments Consulting · 2023-08-11 · $3,500 Meals for Octagam Immune Globulin (Human) · 2023-03-09 · $16 Meals for Octagam Immune Globulin (Human) · 2023-03-03 · $8

2020: $87

Sort by

Payments by company in 2020

Genzyme	Thymoglobulin	$87	1 payment Meals for Thymoglobulin · 2020-01-30 · $87

2019: $20

Sort by

Payments by company in 2019

Ethicon US	Biopatch	$20	2 payments Meals for Biopatch · 2019-10-09 · $10 Meals for Biopatch · 2019-10-09 · $10

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Janssen Research & Development, LLC · A Study of Ad26.Cov2.S for the Prevention of Sarscov2 Mediated Covid19 in Adult Participants · 2022	Their institution	$442,231
PFIZER INC. · A Phase 4 Study Using A Testnegative Design To Evaluate the Effectiveness of A 20valent Pneumococcal Conjugate Vaccine Against Vaccinetype Radiologicallyconfirmed Communityacquired Pneumonia in Adults 65 Years of Age · 2025	Their institution	$204,048
Janssen Research & Development, LLC · A Study of Ad26.Cov2.S for the Prevention of Sarscov2 Mediated Covid19 in Adult Participants · 2023	Their institution	$167,252
Janssen Research & Development, LLC · A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine Expec9v in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years and Older With A History of Urinary Tract Infection in the Past 2 Years · 2025	Their institution	$126,679
Janssen Research & Development, LLC · A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine Expec9v in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years and Older With A History of Urinary Tract Infection in the Past 2 Years · 2023	Their institution	$122,049
PFIZER INC. · A Phase 4 Study Using A Testnegative Design To Evaluate the Effectiveness of A 20valent Pneumococcal Conjugate Vaccine Against Vaccinetype Radiologicallyconfirmed Communityacquired Pneumonia in Adults 65 Years of Age · 2024	Their institution	$108,727
Janssen Research & Development, LLC · A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine Expec9v in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years and Older With A History of Urinary Tract Infection in the Past 2 Years · 2024	Their institution	$108,477
Janssen Research & Development, LLC · A Study of Ad26.Cov2.S for the Prevention of Sarscov2mediated Covid19 in Adults · 2022	Their institution	$76,378
PFIZER INC. · A Phase 4 Study Using A Testnegative Design To Evaluate the Effectiveness of A 20valent Pneumococcal Conjugate Vaccine Against Vaccinetype Radiologicallyconfirmed Communityacquired Pneumonia in Adults 65 Years of Age · 2023	Their institution	$63,026
SCYNEXIS, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Double-Blind Study of Two Treatment Regimens for Candidemia and/Or Invasive Candidiasis: Intravenous Echinocandin Followed By Oral Ibrexafungerp Versus Intravenous Echinocandin Followed By Oral Fluconazole · 2023	Their institution	$62,371
Janssen Research & Development, LLC · A Study of Ad26.Cov2.S for the Prevention of Sarscov2mediated Covid19 in Adults · 2023	Their institution	$34,840
PFIZER INC. · A Phase 3 Study To Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus Rsv Prefusion F Subunit Vaccine in Adults · 2023	Their institution	$32,009
AstraZeneca Pharmaceuticals LP · A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Evaluate the Efficacy and Safety of Tozorakimab (Medi3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (Tilia) · 2024	Their institution	$20,513
PFIZER INC. · A Master Phase 123 Protocol To Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children · 2023	Their institution	$17,500
La Jolla Pharmaceutical Company · A Single-Arm, Open-Label, Prospective, Observational Study To Assess the Safety of Sulbactam-Durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-Calcoaceticus Complex Infection · 2025	Their institution	$17,369
GlaxoSmithKline, LLC. · Phase 3b, Randomized, Observer-Blind. Multicenter Study To Assess the · 2022	Their institution	$14,000
PFIZER INC. · A Phase 2b Openlabel Study To Evaluate the Safety Tolerability and Immunogenicity of Vaccine Candidate Bnt162b2 in Immunocompromised Participants 2 Years of Age · 2023	Their institution	$12,007
AstraZeneca UK Limited · A Phase I-III Randomized Double Blind Study To Evaluate the Safety and Neutralizing Activity of Azd5156-Azd3152 for Pre Exposure Prophylaxis of Covid 19 in Participants With Conditions Causing Immune Impairment · 2025	Their institution	$12,000
SCYNEXIS, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Double-Blind Study of Two Treatment Regimens for Candidemia and/Or Invasive Candidiasis: Intravenous Echinocandin Followed By Oral Ibrexafungerp Versus Intravenous Echinocandin Followed By Oral Fluconazole · 2025	Their institution	$6,761
AstraZeneca Pharmaceuticals LP · A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Evaluate the Efficacy and Safety of Tozorakimab (Medi3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (Tilia) · 2025	Their institution	$2,250
AstraZeneca Pharmaceuticals LP · A Phase 3 Randomized Open Label Study To Assess the Immunogenicity and Safety of Ivx A12 When Co-Administered With A Licensed Influenza Vaccine · 2025	Their institution	$2,022
SCYNEXIS, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Double-Blind Study of Two Treatment Regimens for Candidemia and/Or Invasive Candidiasis: Intravenous Echinocandin Followed By Oral Ibrexafungerp Versus Intravenous Echinocandin Followed By Oral Fluconazole · 2024	Their institution	$1,070
GlaxoSmithKline, LLC. · Phase 3b, Randomized, Observer-Blind. Multicenter Study To Assess the · 2023	Their institution	$1,000

Professional record

NPI: 1083938997
Licence: LA MD.207707
Trained: Louisiana State University School of Medicine in New Orleans, 2010 · 16 years ago
Group: Ochsner Clinic LLC
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Medicaid ID: LA 2397346, MS 07584764
Taxonomy: Federal specialty code 207RI0200X (207RI0200X); Student in a training program (390200000X)
Mailing address: 1514 Jefferson Hwy, New Orleans, LA, 70121
NPI first listed: 2010-03-22
NPI last updated: 2015-10-14

This is when the NPI record was last certified, not a medical board exam.